<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Robotics Daily · Cyborgs</title><description>Every Robotics Daily capsule in the segment Cyborgs, the latest first.</description><link>https://roboticsdaily.robotshop.com/</link><language>en</language><atom:link href="https://roboticsdaily.robotshop.com/feeds/cyborgs.xml" rel="self" type="application/rss+xml"/><item><title>WIRobotics signs Ottobock to sell its WIM S wearable robot in North America</title><link>https://roboticsdaily.robotshop.com/capsules/wirobotics-ottobock-wim-s-north-america-2026-11-16/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/wirobotics-ottobock-wim-s-north-america-2026-11-16/</guid><description>WIRobotics USA agreed with Otto Bock HealthCare to distribute the WIM S walking-assist wearable in the US and Canada, starting in the US.</description><pubDate>Tue, 17 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/wirobotics-ottobock-wim-s-north-america-2026-11-16.DRAPNFKf_1tTYxI.jpeg&quot; alt=&quot;Two people walking outdoors in a garden, cropped at the torso to show the belt-mounted motor unit and thigh-strapped frames of a wearable walking-assist robot on each of them.&quot; /&gt;&lt;figcaption&gt;Image: WIRobotics / official website · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;WIRobotics USA Inc. has signed a distribution and sales agreement with Otto Bock HealthCare LP for North America, according to a WIRobotics release dated 16 November 2026. The agreement, signed on 15 October, covers the United States and Canada. Sales start in the US, and Canada is described as a possible later step.&lt;/p&gt;&lt;p&gt;The first product is the WIM S, a wearable robot that assists walking. It will be sold through Ottobock&amp;#39;s online platform and the WIRobotics USA store, and users will be able to try it at selected orthotic and prosthetic clinics. The release says more US locations will be considered.&lt;/p&gt;&lt;p&gt;WIRobotics says its WIM series has passed 4,000 cumulative units sold, in South Korea, Europe, China and Japan.&lt;/p&gt;&lt;p&gt;A medical version, WIM Medi, is in development but is not part of this agreement; the release says medical channels depend on regulatory authorisation and a separate agreement. It gives no price.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Huawei unveils the Sense G1, its first continuous glucose monitor</title><link>https://roboticsdaily.robotshop.com/capsules/huawei-g1-cgm-unveil-2026-11/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/huawei-g1-cgm-unveil-2026-11/</guid><description>Huawei announced the Sense G1 on 13 Nov. 2026, a two-week arm-worn glucose sensor that streams readings to phones and watches, after a reported Class III approval in China.</description><pubDate>Mon, 16 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/huawei-g1-cgm-unveil-2026-11.BlT7lIeA_1Jvqj9.jpeg&quot; alt=&quot;A person raising an arm to show a Huawei smartwatch displaying a glucose reading of 6.1 mmol/L and trend graph, with a round white continuous glucose monitor sensor patch stuck to the back of the upper arm.&quot; /&gt;&lt;figcaption&gt;Image: Huawei (via Huawei Central) · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Huawei unveiled the Sense G1, its first continuous glucose monitor, on 13 November 2026. The sensor is worn on the upper arm for up to two weeks, measures glucose around the clock and sends readings to a smartphone or a smartwatch, with alerts for abnormal values. It can be worn while swimming.&lt;/p&gt;&lt;p&gt;Huawei Central reports a mean absolute relative difference below 10% and a data delay of about 5 to 15 minutes. Those figures come from that outlet; no Huawei release or accuracy study was available to confirm them.&lt;/p&gt;&lt;p&gt;According to vcbeat, republished by 36Kr on 3 November, China&amp;#39;s National Medical Products Administration approved the system as a Class III medical device on 30 October, Huawei&amp;#39;s first device in that class. The registration covers adults over 18 with diabetes, needs no user calibration and allows up to 16 days of wear. The approval date rests on that report rather than on the regulator&amp;#39;s register.&lt;/p&gt;&lt;p&gt;Huawei has not announced a price or a sale date.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>An EEG interface lets wearers command two extra robotic arms</title><link>https://roboticsdaily.robotshop.com/capsules/imperial-tactile-bci-supernumerary-arms-natcomms-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/imperial-tactile-bci-supernumerary-arms-natcomms-2026/</guid><description>Imperial College London used wrist and elbow vibrations to evoke P300 brain responses, letting 10 volunteers command two extra robotic arms while their own hands kept working (Nature Communications, 2 July 2026).</description><pubDate>Mon, 16 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/imperial-tactile-bci-supernumerary-arms-natcomms-2026.q30KaZEt_Z1UdlAX.jpeg&quot; alt=&quot;Illustration of a person wearing an EEG cap and a tactile wristband on each arm, with two extra robotic arms mounted on the shoulders holding a cup and straw while the person&amp;#39;s own hands carry a box on a table.&quot; /&gt;&lt;figcaption&gt;Image: Jia et al., Nature Communications 2026 (CC BY 4.0) · cc-by&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;A team led by Dario Farina at Imperial College London, with first author Tianyu Jia, published a brain-computer interface for extra robotic limbs in Nature Communications on 2 July 2026. The study drew wider attention in November through PsyPost&amp;#39;s coverage.&lt;/p&gt;&lt;p&gt;The interface reads brain activity with a 64-electrode EEG cap. Four small vibrators near the wrists and elbows pulse in random order; the user silently attends to the one linked to the desired command, which produces a P300 response the decoder matches to that vibrator. Each detected choice triggers a preset movement of one of two tabletop robotic arms.&lt;/p&gt;&lt;p&gt;Ten able-bodied adults trained for three days while balancing a ball on a tray with their own hands. Command accuracy during that dual task rose from 53.1% on day 1 to 69.7% on day 3, against 79.1% when sitting still, and by day 3 the gap was no longer statistically significant.&lt;/p&gt;&lt;p&gt;Each command still takes several seconds, the arms run preprogrammed routines rather than proportional control, and none of the volunteers had a disability.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Neuralink registers PRIME2 trial, adding chronic stroke to its implant studies</title><link>https://roboticsdaily.robotshop.com/capsules/neuralink-prime2-nct07929792-stroke-2026-11-10/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/neuralink-prime2-nct07929792-stroke-2026-11-10/</guid><description>Neuralink listed PRIME2 on ClinicalTrials.gov on 10 November 2026: up to 10 adults with spinal cord injury, ALS or chronic stroke, starting at the University of Miami.</description><pubDate>Thu, 12 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/neuralink-prime2-nct07929792-stroke-2026-11-10.CTRe_pYt_Z1wPU3C.jpeg&quot; alt=&quot;A Neuralink participant, partly out of frame at the right edge, sits beside two laptops, one showing neural signal traces and the other a grid-based cursor-control task with a bits-per-second score of 4.18.&quot; /&gt;&lt;figcaption&gt;Image: Neuralink / website · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Neuralink registered a new early feasibility study, PRIME2, on ClinicalTrials.gov on 10 November 2026 (NCT07929792). It will place the company&amp;#39;s N1 brain-computer interface with its R1 surgical robot, which inserts the implant&amp;#39;s electrode threads, and test whether participants can control external devices.&lt;/p&gt;&lt;p&gt;The record lists up to 10 adults aged 18 or older with severe upper-limb impairment from spinal cord injury, ALS or chronic ischemic stroke. Chronic stroke is a new population for Neuralink&amp;#39;s registered trials. Status is recruiting, with an estimated start in November 2026. One site is listed, the University of Miami; the study summary mentions up to five U.S. sites.&lt;/p&gt;&lt;p&gt;A registry entry is not a result: it names no participant, no implant date and no outcome data.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Google smartwatch model flags signs of hypertension in a 196-person study</title><link>https://roboticsdaily.robotshop.com/capsules/google-smartwatch-ai-hypertension-nature-2026-11/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/google-smartwatch-ai-hypertension-nature-2026-11/</guid><description>On 5 November 2026 Google Research reported in Nature a model that screens for hypertension from consumer smartwatch signals, in early feasibility work.</description><pubDate>Mon, 09 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/google-smartwatch-ai-hypertension-nature-2026-11.BhK7rxSf_ZaF3ed.jpeg&quot; alt=&quot;Anatomical illustration of a man&amp;#39;s torso with the heart and arteries in red, a dashed line running down his arm to a wrist-worn sensor band, beside a magnified skin patch showing a photoplethysmography light sensor and a pulse waveform.&quot; /&gt;&lt;figcaption&gt;Image: Google Research / research blog (Di Achille and Poh) · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Google Research published a study in Nature on 5 November 2026 describing a model that detects signs of hypertension from a consumer smartwatch, without an arm cuff. It reads photoplethysmography and accelerometer signals and uses several days of wear data rather than a single reading.&lt;/p&gt;&lt;p&gt;The team pre-trained it on 492,347 hours of unlabeled sensor data from 2,109 participants, then validated it in a prospective study of 196 people at five US sites against 24-hour ambulatory blood pressure monitoring. In initial screening the model reached 65.8% sensitivity and 90.0% specificity, against 55.3% and 77.8% for office measurement. In a confirmatory subset of 48 participants, sensitivity was 78.4% and specificity 90.9%.&lt;/p&gt;&lt;p&gt;The authors describe the work as early feasibility research. Participants had no known cardiovascular disease and took no blood pressure medication, and the confirmatory subset is small. The tool is not meant to replace a cuff or to give a standalone diagnosis, and Google states it does not indicate a commercial product feature.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>ETH Zurich implant turns excess blood glucose into gluconate in mice</title><link>https://roboticsdaily.robotshop.com/capsules/eth-zurich-echo-glucose-electrocatalytic-implant-science-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/eth-zurich-echo-glucose-electrocatalytic-implant-science-2026/</guid><description>A wirelessly powered electrocatalytic implant regulated blood sugar in diabetic mice over six weeks, according to a Science paper from ETH Zurich dated 22 October 2026.</description><pubDate>Mon, 09 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/eth-zurich-echo-glucose-electrocatalytic-implant-science-2026.DDF0e_Lu_1O94rB.jpeg&quot; alt=&quot;Black-and-white electron microscope image of the implant&amp;#39;s catalyst, rose-shaped clusters of tiny gold platelets dusted with platinum particles, resting on a dark textured surface.&quot; /&gt;&lt;figcaption&gt;Image: Debasis Maity, Biotechnology and Bioengineering Group / ETH Zurich · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;A team led by Martin Fussenegger at ETH Zurich reported on 22 October 2026, in Science, an implant that lowers blood sugar without drugs, cells or enzymes. It uses an inorganic catalyst: graphite felt studded with gold nanoclusters and decorated with platinum particles.&lt;/p&gt;&lt;p&gt;The device is powered wirelessly at 13.56 MHz and converts excess glucose into gluconate, which the kidneys excrete in urine. A standard glucose sensor reports tissue levels, a signal passes over Bluetooth from a smartphone or smartwatch, and the catalyst switches off once glucose reaches the target range.&lt;/p&gt;&lt;p&gt;In a laboratory test the catalyst converted glucose in a 5-litre nutrient solution, roughly the volume of human blood. In mice with type 2 diabetes the implant held blood sugar in the normal range, and over six weeks the animals lost weight. The system has not been tested in humans. IEEE Spectrum reports that the team plans studies in larger animals, such as rabbits and pigs, before any human trial.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Northwestern smartwatch prototypes read hand gestures, with prosthetic control as a goal</title><link>https://roboticsdaily.robotshop.com/capsules/northwestern-eitwatch-smartwatch-prosthetic-2026-11/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/northwestern-eitwatch-smartwatch-prosthetic-2026-11/</guid><description>On 4 November 2026 Northwestern&apos;s SPICE Lab presented EITWatch and TransfHAR, two smartwatch sensing prototypes, at ACM UIST 2026.</description><pubDate>Sat, 07 Nov 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/northwestern-eitwatch-smartwatch-prosthetic-2026-11.C5KN9D-T_Z1fxIJG.jpeg&quot; alt=&quot;A person seen from behind raises a hand in a pinching gesture, wearing a smartwatch with a bare sensor circuit board strapped to the wrist beside it.&quot; /&gt;&lt;figcaption&gt;Image: Northwestern University · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Northwestern University reported on 4 November 2026 that its SPICE Lab, led by Karan Ahuja, presented two smartwatch sensing projects at the ACM Symposium on User Interface Software and Technology (UIST) 2026.&lt;/p&gt;&lt;p&gt;EITWatch puts eight electrodes on the back of a watch and uses electrical impedance tomography to map muscles and tendons in the wrist. It recognized six common hand gestures with over 92 percent accuracy and five subtler finger movements with over 91 percent accuracy. It is a research prototype that works best when calibrated to a single user.&lt;/p&gt;&lt;p&gt;TransfHAR uses the watch&amp;#39;s accelerometer and gyroscope. It was pretrained on more than 2,700 hours of public movement data, and in a study with 10 participants it recognized seven new activities with about 90 percent accuracy after a single one-minute recording of each.&lt;/p&gt;&lt;p&gt;The team says it is exploring whether this kind of sensing could help control prosthetic hands. That is a possible use and was not demonstrated in the work, and neither system is a product.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>NUS weaves a working touchscreen display into a garment sleeve</title><link>https://roboticsdaily.robotshop.com/capsules/nus-woven-fibre-touchscreen-garment-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/nus-woven-fibre-touchscreen-garment-2026/</guid><description>A National University of Singapore team wove a 96x54-pixel touch display from 54 LED fibres into a sleeve, a result published in Nature on 21 October 2026.</description><pubDate>Sat, 31 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/nus-woven-fibre-touchscreen-garment-2026.D_NyOk6Z_1wDbmG.jpeg&quot; alt=&quot;An animated rendering of a finger tapping a glowing pixel display on a black sleeve that reads HELLO FIBRE above app icons, beside a spool of rainbow-lit fibre.&quot; /&gt;&lt;figcaption&gt;Image: NUS / YouTube · video-thumbnail&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Researchers at the National University of Singapore&amp;#39;s College of Design and Engineering, led by Assistant Professor Tural Khudiyev, have built a touchscreen into the forearm of a garment. NUS announced the work on 22 October 2026 and says it was published in Nature on 21 October.&lt;/p&gt;&lt;p&gt;The display is 168 by 105 mm with 96 by 54 pixels. It is woven from 54 pixel fibres, each about 1 mm thick and 10 m long and carrying 96 LEDs, adding up to more than 5,000 chips and over 20,000 electrical connections. It runs at 30 frames per second with 8-bit colour and can play video, with synchronised audio at 25 frames per second. NUS says light output and touch response were nearly unchanged after 50 detergent washes and 1,000 bends around a 5 mm radius.&lt;/p&gt;&lt;p&gt;The university gives no product timeline, cost or detail on how the screen is powered for all-day wear. The image is a frame from the NUS announcement video, an animated rendering rather than a photograph of the prototype.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>NeuroXess raises RMB 700 million for its implantable brain-computer interface</title><link>https://roboticsdaily.robotshop.com/capsules/neuroxess-series-b-rmb700m-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/neuroxess-series-b-rmb700m-2026/</guid><description>The Shanghai company closed a Series B on 28 October 2026 to fund a registration trial at nearly 20 hospitals and a factory planned for 10,000 systems a year.</description><pubDate>Wed, 28 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/neuroxess-series-b-rmb700m-2026.Bn631aiC_G0SV4.jpeg&quot; alt=&quot;A man with glasses lying in a care bed while an older woman in a red blouse stands beside him smiling and holding a small figurine.&quot; /&gt;&lt;figcaption&gt;Image: NeuroXess / YouTube · video-thumbnail&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;NeuroXess, a brain-computer interface company based in Shanghai, closed a Series B round of RMB 700 million on 28 October 2026, according to TechNode. SDIC Juli, Shenzhen Capital Group and Qinzhi Capital co-led it.&lt;/p&gt;&lt;p&gt;The company reports 65 completed clinical cases. A registration trial, the pivotal study a device maker submits to the regulator for market approval, began in July 2026 at nearly 20 hospitals. NeuroXess says its implantable systems combine flexible electrodes with wireless power and data transmission, and decode movement and speech to control external devices.&lt;/p&gt;&lt;p&gt;The proceeds go to multicentre trials, regulatory submissions, manufacturing capacity and a next-generation product. NeuroXess says it is building a 14,300-square-metre factory with a planned capacity of 10,000 systems a year. The clinical figures and the capacity plan are the company&amp;#39;s own statements as relayed by TechNode; the report cites no trial registry entry.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Fraunhofer ear EEG patch keeps stable contact for 24 hours</title><link>https://roboticsdaily.robotshop.com/capsules/fraunhofer-treegrid-24h-eeg-patch-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/fraunhofer-treegrid-24h-eeg-patch-2026/</guid><description>The trEEGrid electrode patch recorded brain signals through daytime tasks and a night of sleep at home in a ten-person study, reported on 27 October 2026.</description><pubDate>Wed, 28 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/fraunhofer-treegrid-24h-eeg-patch-2026.fQKHu1-r_1JxybF.jpeg&quot; alt=&quot;Profile of a woman with a flexible electrode patch on her temple and cheek, with the caption &amp;#39;Designed for comfortable long-term recordings of EEG, EOG and EMG&amp;#39;.&quot; /&gt;&lt;figcaption&gt;Image: Fraunhofer IDMT / YouTube · video-thumbnail&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;The Fraunhofer Institute for Digital Media Technology IDMT in Oldenburg, Germany, reported on 27 October 2026 that its trEEGrid ear electrode patch recorded stable brain signals over about 24 hours of continuous wear. The study, in the journal Sensors, covered 10 participants.&lt;/p&gt;&lt;p&gt;trEEGrid is a flexible, eight-channel electrode patch worn behind the ear, with a miniaturised amplifier prototype developed by Brain Products GmbH. A base unit in a waist or chest pocket supplies power. Participants wore it through daytime tasks and an overnight sleep recorded at home.&lt;/p&gt;&lt;p&gt;Average electrode impedance, a measure of how well the skin contact holds, stayed below 140 kilohms on all eight channels on day one and below 100 kilohms on day two. The recorded signals distinguished easy from difficult Sudoku levels. The sample is small and the work checks contact quality and signal usefulness, not clinical or consumer performance. The Medical Xpress report is the only source read; the paper itself sits behind a publisher page that blocked retrieval.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Senseonics starts first-in-human study of an implantable CGM with no on-body part</title><link>https://roboticsdaily.robotshop.com/capsules/senseonics-freedom-cgm-first-in-human-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/senseonics-freedom-cgm-first-in-human-2026/</guid><description>Freedom adds a battery and Bluetooth to the implanted Eversense 365 sensor so it can talk to a phone directly; Senseonics announced the study on 26 October 2026.</description><pubDate>Wed, 28 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/senseonics-freedom-cgm-first-in-human-2026.DzQjjqrx_2tv5c6.jpeg&quot; alt=&quot;A close-up of a translucent blue implantable glucose sensor lying horizontally on a white background, with its dark internal battery and two colourful electronic chips visible through the casing.&quot; /&gt;&lt;figcaption&gt;Image: Senseonics / Eversense 365 media kit · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Senseonics said on 26 October 2026 that it has started a first-in-human early feasibility study of Freedom, an investigational implantable continuous glucose monitor designed to have no external on-body transmitter.&lt;/p&gt;&lt;p&gt;Freedom builds on the sensing technology of Eversense 365 and adds an integrated battery and embedded Bluetooth, so the implanted sensor communicates directly with a mobile device. It is designed for one year of sensing from a single sensor. The study evaluates clinical safety and device functionality, including that direct Bluetooth link.&lt;/p&gt;&lt;p&gt;Preclinical testing in the second quarter of 2026 ran about seven weeks and logged more than 18,500 communication data points; the company says the preferred design achieved 100% communication success within the target distance. Senseonics expects to start a pivotal study in 2027 and targets a potential commercial launch in 2028. The release gives no participant count or study sites. The image shows the current Eversense 365 sensor, not Freedom.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>FDA lets Paradromics recruit brain-implant study participants across the United States</title><link>https://roboticsdaily.robotshop.com/capsules/paradromics-connect-one-nationwide-recruitment-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/paradromics-connect-one-nationwide-recruitment-2026/</guid><description>Paradromics said on 26 October 2026 that the FDA approved a change to its Connect-One study, removing the rule that participants live within four hours of a site.</description><pubDate>Tue, 27 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/paradromics-connect-one-nationwide-recruitment-2026.DXa0Bf71_Z1V9llf.jpeg&quot; alt=&quot;A split frame: on the left a smiling woman with glasses seated in an armchair with a small device strapped to her chest, on the right a man in a cap smiling behind a closed laptop on a table.&quot; /&gt;&lt;figcaption&gt;Image: Paradromics / YouTube · video-thumbnail&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Paradromics announced on 26 October 2026 that the U.S. Food and Drug Administration approved an amendment to the protocol of Connect-One, the early feasibility study of its Connexus brain-computer interface. The change removes the requirement that candidates live within a four-hour drive of a study site, opening recruitment across the continental United States.&lt;/p&gt;&lt;p&gt;The study runs at UC Davis Health, Mass General Brigham and University of Michigan Health. The FDA first authorized it in November 2025, and the first long-term implantation was completed at University of Michigan Health in June 2026. Paradromics says that first participant is now using the device to communicate.&lt;/p&gt;&lt;p&gt;The company gave no enrolment target and no count of participants implanted so far, and the arrangements for people travelling long distances still have to be set with the sites and their review boards. The device remains investigational. Distance from a trial site had limited who could take part; the amendment widens the pool of people with paralysis who can apply.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>A non-invasive brain-computer interface responds to a third of unresponsive brain-injury patients</title><link>https://roboticsdaily.robotshop.com/capsules/columbia-eeg-bci-unresponsive-icu-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/columbia-eeg-bci-unresponsive-icu-2026/</guid><description>A Columbia study in Brain, published on 22 October 2026, found that 13 of 41 clinically unresponsive patients could control an EEG brain-computer interface.</description><pubDate>Tue, 27 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/columbia-eeg-bci-unresponsive-icu-2026.iwMBxfGd_Z1aitoC.jpeg&quot; alt=&quot;A seated volunteer wears an EEG electrode cap while researchers watch the live brain-signal trace on a monitor.&quot; /&gt;&lt;figcaption&gt;Image: Rudy Diaz / Columbia University Irving Medical Center · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;A study published in Brain on 22 October 2026 by researchers at Columbia University Irving Medical Center and NewYork-Presbyterian tested a non-invasive EEG brain-computer interface on 41 clinically unresponsive patients with acute brain injury in intensive care, alongside 22 conscious critically ill patients and eight healthy volunteers.&lt;/p&gt;&lt;p&gt;Thirteen of the 41 unresponsive patients, or 32%, gained control of the interface, which lets a user change a tone by imagining movement. Control was associated with recovery: six of those 13 were functionally independent at 12 months, against two of the 28 patients who did not gain control. The authors present control of the interface as a strong predictor of outcome.&lt;/p&gt;&lt;p&gt;It is an observational result from a single centre, so it shows an association, not a cause. The system controls a tone and cannot yet express needs or answer questions, and the findings have not been replicated at other hospitals.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Phantom Neuro implants an under-skin muscle sensor for prosthetic arms in its first two patients</title><link>https://roboticsdaily.robotshop.com/capsules/phantom-neuro-phantom-x-first-human-2026-10/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/phantom-neuro-phantom-x-first-human-2026-10/</guid><description>Phantom Neuro&apos;s implant, which reads forearm muscle signals to drive a prosthetic arm, went into its first two patients in Melbourne, IEEE Spectrum reported on 20 October 2026.</description><pubDate>Tue, 27 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/phantom-neuro-phantom-x-first-human-2026-10.BwLMjU9i_1j2di6.jpeg&quot; alt=&quot;A tattooed man smiles as he speaks off camera in a bright room, in IEEE Spectrum&amp;#39;s video about Phantom Neuro&amp;#39;s first user.&quot; /&gt;&lt;figcaption&gt;Image: IEEE Spectrum / YouTube · video-thumbnail&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Austin-based Phantom Neuro has implanted its device in its first two patients, both in Melbourne, Australia, IEEE Spectrum reported on 20 October 2026. The implant, about 2 by 10 centimetres, sits under the skin of the forearm and records the electrical activity of the muscles, which it translates into commands for a prosthetic arm made by another company.&lt;/p&gt;&lt;p&gt;The procedures are part of an early feasibility trial approved by Australian regulators in April 2026, whose first goal is safety. The company reports strong and consistent signals so far, from one or two patients. IEEE Spectrum says the first operation took about four hours and the second about 45 minutes, without general anaesthesia.&lt;/p&gt;&lt;p&gt;The implant cannot yet combine movements, such as turning the wrist while closing the fingers. Phantom Neuro hopes for U.S. approval for upper-limb control within two to three years. Reading muscles under the skin, rather than through electrodes on its surface, aims to give amputees a steadier signal day to day.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Science Corp reports a 29-letter average vision gain at 36 months with its PRIMA retinal implant</title><link>https://roboticsdaily.robotshop.com/capsules/science-prima-36-month-results-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/science-prima-36-month-results-2026/</guid><description>Science Corporation presented 36-month PRIMAvera results on 5 October 2026: patients with geographic atrophy gained 29 letters of visual acuity on average.</description><pubDate>Tue, 27 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/science-prima-36-month-results-2026.QFlWHRdy_Z1BM5N0.jpeg&quot; alt=&quot;A line chart of average visual acuity improvement over 36 months, showing eyes with the PRIMA implant gaining about 29 letters by month 36 while eyes without it drift to about minus 2 letters.&quot; /&gt;&lt;figcaption&gt;Image: Science Corporation / newsroom · press-kit&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;Science Corporation presented 36-month results from PRIMAvera, the European trial of its PRIMA retinal implant, at the EURETINA congress in Vienna, announced on 5 October 2026. The implant is a wireless photovoltaic chip placed under the retina of people who have lost central vision to geographic atrophy, an advanced form of age-related macular degeneration.&lt;/p&gt;&lt;p&gt;Thirty-eight patients were implanted at 17 sites in five countries; 18 were evaluable for efficacy at 36 months. Their mean improvement was 29 letters, nearly six lines on an eye chart, up from 24.5 letters at 12 months, and 14 of the 18 gained at least 15 letters. The company reports no new safety signal between months 12 and 36.&lt;/p&gt;&lt;p&gt;These are company-reported conference results, with fewer than half the patients evaluable for efficacy, and no peer-reviewed paper on the 36-month data yet. PRIMA is sold in Europe and the United Kingdom and awaits a decision from the U.S. FDA.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item><item><title>Wandercraft acquires Ekso Bionics and brings four medical exoskeletons under one roof</title><link>https://roboticsdaily.robotshop.com/capsules/wandercraft-ekso-bionics-acquisition-2026/</link><guid isPermaLink="true">https://roboticsdaily.robotshop.com/capsules/wandercraft-ekso-bionics-acquisition-2026/</guid><description>Wandercraft announced on 1 October 2026 that it had acquired Ekso Bionics from a ChronoScale subsidiary, combining four medical exoskeletons.</description><pubDate>Tue, 27 Oct 2026 00:00:00 GMT</pubDate><content:encoded>&lt;figure&gt;&lt;img src=&quot;https://roboticsdaily.robotshop.com/_astro/wandercraft-ekso-bionics-acquisition-2026.C_H19EEt_19auvi.jpeg&quot; alt=&quot;A woman standing upright in a Wandercraft Eve personal exoskeleton on a wooden deck, holding its handles.&quot; /&gt;&lt;figcaption&gt;Image: Wandercraft / YouTube · video-thumbnail&lt;/figcaption&gt;&lt;/figure&gt;&lt;p&gt;French exoskeleton maker Wandercraft announced on 1 October 2026 that it had acquired Ekso Bionics from a subsidiary of ChronoScale Holdings, with signing and closing on the same day. The combined company sells four medical exoskeletons: Atalante X and EksoNR for clinical rehabilitation, and Eve and Indego for personal use.&lt;/p&gt;&lt;p&gt;The two companies say their rehabilitation systems are used for walking training in more than 700 rehabilitation and research centres worldwide. Wandercraft chief executive Matthieu Masselin presented the deal as a way to widen access to robotic mobility for people who cannot walk unaided. All four products remain supported.&lt;/p&gt;&lt;p&gt;The financial terms were not disclosed, and it is not yet clear how the product lines will be combined over time. The deal consolidates a small market in which few companies have reached clinical scale.&lt;/p&gt;</content:encoded><category>Cyborgs</category></item></channel></rss>